Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


12.03.2018

1 Ann Oncol
2 BMC Cancer
1 Cancer Chemother Pharmacol
1 Cancer Res
1 Clin Cancer Res
1 Eur J Obstet Gynecol Reprod Biol
2 Gynecol Oncol
1 Oncol Rep
2 Oncology (Williston Park)
1 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. PARK SB, Kwok JB, Asher R, Lee CK, et al
    Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.
    Ann Oncol. 2017;28:2733-2740.
    PubMed     Text format     Abstract available


    BMC Cancer

  2. LEVAN K, Mehryar M, Mateoiu C, Albertsson P, et al
    Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.
    BMC Cancer. 2017;17:303.
    PubMed     Text format     Abstract available

  3. HANLEY GE, McAlpine JN, Miller D, Huntsman D, et al
    A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    BMC Cancer. 2018;18:254.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  4. TAKASAKI K, Miyamoto M, Takano M, Soyama H, et al
    Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis.
    Cancer Chemother Pharmacol. 2018 Mar 2. pii: 10.1007/s00280-018-3552.
    PubMed     Text format     Abstract available


    Cancer Res

  5. CONDELLO S, Sima LE, Ivan C, Cardenas H, et al
    Tissue transglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche.
    Cancer Res. 2018 Mar 6. pii: 0008-5472.CAN-17-2319.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  6. MATEI D, Ghamande S, Roman LD, Alvarez Secord A, et al
    A Phase 1 Clinical Trial of Guadecitabine and Carboplatin In Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic And Pharmacodynamic Analyses.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-3055.
    PubMed     Text format     Abstract available


    Eur J Obstet Gynecol Reprod Biol

  7. GHANEM AI, Khan NT, Mahan M, Ibrahim A, et al
    The impact of lymphadenectomy on survival endpoints in women with early stage uterine endometrioid carcinoma: A matched analysis.
    Eur J Obstet Gynecol Reprod Biol. 2016;210:225-230.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  8. XIAO X, Dong D, He W, Song L, et al
    Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Gynecol Oncol. 2018 Feb 26. pii: S0090-8258(18)30128.
    PubMed     Text format     Abstract available

  9. SCHUURMAN MS, Kruitwagen RFPM, Portielje JEA, Roes EM, et al
    Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis.
    Gynecol Oncol. 2018 Mar 4. pii: S0090-8258(18)30136.
    PubMed     Text format     Abstract available


    Oncol Rep

  10. SONG K, Lv T, Chen Y, Diao Y, et al
    Emodin inhibits TGF-beta2 by activating the FOXD3/miR199a axis in ovarian cancer cells in vitro.
    Oncol Rep. 2018 Mar 6. doi: 10.3892/or.2018.6301.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  11. OZOLS RF
    Counterpoint: Is There Still a Role for Intraperitoneal Platinum Therapy in Ovarian Cancer?
    Oncology (Williston Park). 2018;32:75.
    PubMed     Text format    

  12. FUJIWARA K
    Point: Is There Still a Role for Intraperitoneal Platinum Therapy in Ovarian Cancer?
    Oncology (Williston Park). 2018;32:75-7.
    PubMed     Text format    


    PLoS One

  13. HOU S, Dai J
    Transcriptome-based signature predicts the effect of taxol in serous ovarian cancer.
    PLoS One. 2018;13:e0192812.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  14. PURAYIL HT, Daaka Y
    beta-Arrestin1 mediates hMENA expression and ovarian cancer metastasis.
    Proc Natl Acad Sci U S A. 2018 Mar 7. pii: 1802643115.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: